Overview

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Status:
Completed

Trial end date:
2019-11-12

Target enrollment:

Participant gender:

Summary

Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)

Phase:

Phase 4

Details

Lead Sponsor:

University of California, San Diego

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Aflibercept